112
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication

ORCID Icon, , , ORCID Icon &
Pages 1287-1295 | Received 17 Jun 2023, Accepted 07 Nov 2023, Published online: 29 Nov 2023

References

  • Scadding GK, Scadding GW. Innate and adaptive immunity: ILC2 and Th2 cells in upper and lower airway allergic diseases. J Allergy Clin Immunol Pract. 2021;9:1851–1857.
  • Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576–02021. doi:10.1183/23120541.00576-2021
  • Brusselle GG, Koppelman GH, Taichman DB. Biologic therapies for severe asthma. Taichman DB, editor. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506
  • Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149:1309–1317.e12.
  • Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:10.1016/S0140-6736(19)31881-1
  • Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi:10.1016/j.jaci.2020.05.032
  • Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:1141–1153.
  • Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139. doi:10.1056/NEJMoa1314768
  • Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252. doi:10.1056/NEJMoa1507247
  • Simpson EL, Lacour J-P, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242–255. doi:10.1111/bjd.18898
  • Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022;10:11–25. doi:10.1016/S2213-2600(21)00322-2
  • Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55:1.
  • Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A Study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10:2646–2656. doi:10.1016/j.jaip.2022.05.042
  • Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. doi:10.1111/cea.13614
  • Humbert M, Bourdin A, Taillé C, et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022;60:2103130.
  • Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol. 2019;19:53.
  • Larger E, Alexandre-Heymann L, Pilet S, Raoul T, Perray L, Maravic M. Polypharmacy in diabetes: a nation-wide, pharmacy-based, observational study. Diabetes Epidemiol Manag. 2022;8:100088. doi:10.1016/j.deman.2022.100088
  • Joumaa H, Sigogne R, Maravic M, Perray L, Bourdin A, Roche N. Artificial intelligence to differentiate asthma from COPD in medico-administrative databases. BMC Pulm Med. 2022;22(1):357. doi:10.1186/s12890-022-02144-2
  • Vilcu A-M, Blanchon T, Sabatte L, et al. Cross-validation of an algorithm detecting acute gastroenteritis episodes from prescribed drug dispensing data in France: comparison with clinical data reported in a primary care surveillance system, winter seasons 2014/15 to 2016/17. BMC Med Res Methodol. 2019;19(1):110. doi:10.1186/s12874-019-0745-5
  • Panettieri RA, Ledford DK, Chipps BE, et al. Biologic use and outcomes among adults with severe asthma treated by US subspecialists. Ann Allergy Asthma Immunol. 2022;129:467–474.e3.
  • Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021;30(162):210067. doi:10.1183/16000617.0067-2021
  • Isaman D, Khan A, Lee S, et al. Oral corticosteroid burden and Healthcare Resource Utilization (HCRU) in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) undergoing Functional Endoscopic Sinonasal Surgery (FESS): a Real-World Retrospective Cohort Study. J Allergy Clin Immunol. 2023;151:AB201.
  • Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2023;78(9):860–867. doi:10.1136/thorax-2022-219642
  • Darmon D, Laforest L, Van Ganse E, Petrazzuoli F, Van Weel C, Letrilliart L. Prescription of antibiotics and anxiolytics/hypnotics to asthmatic patients in general practice: a cross-sectional study based on French and Italian prescribing data. BMC Fam Pract. 2015;16(1):14. doi:10.1186/s12875-015-0222-0
  • Workman AD, Dattilo LW, Mitchell MB, Rathi VK, Bhattacharyya N. Rates of antidepressant, anxiolytic, and ADHD medication use among patients undergoing ESS. Ann Otol Rhinol Laryngol. 2023;000348942311790. doi:10.1177/00034894231179016
  • Bourdin A, Adcock I, Berger P, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev. 2020;29(155):190085. doi:10.1183/16000617.0085-2019
  • Vanderweil SG, Tsai C, Pelletier AJ, et al. Inappropriate use of antibiotics for acute asthma in United States emergency departments. Acad Emerg Med. 2008;15(8):736–743. doi:10.1111/j.1553-2712.2008.00167.x